Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Radiology
Published in: Japanese Journal of Radiology 7/2016

01-07-2016 | Review

Update on advances in molecular PET in urological oncology

Authors: Kazuhiro Kitajima, Shingo Yamamoto, Kazuhito Fukushima, Ryogo Minamimoto, Takao Kamai, Hossein Jadvar

Published in: Japanese Journal of Radiology | Issue 7/2016

Login to get access

Abstract

Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxy-d-glucose (18F-FDG) has emerged as a powerful tool for the combined metabolic and anatomic evaluation of many cancers. In urological oncology, however, the use of 18F-FDG has been limited by a generally low tumor uptake, and physiological excretion of FDG through the urinary system. 18F-FDG PET/CT is useful when applied to specific indications in selected patients with urological malignancy. New radiotracers and positron emission tomography/magnetic resonance imaging (PET/MRI) are expected to further improve the performance of PET in uro-oncology.
Literature
1.
Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012;12:464–74.PubMedPubMedCentralCrossRef
2.
Ferda J, Ferdova E, Hora M, Hes O, Finek J, Topolcan O, et al. FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. Anticancer Res. 2013;33:2665–72.PubMed
3.
Win AZ, Aparici CM. Clinical effectiveness of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in management of renal cell carcinoma: a single institution experience. World J Nucl Med. 2015;14:36–40.PubMedPubMedCentralCrossRef
4.
Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int. 2009;103:615–9.PubMedCrossRef
5.
Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K. The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol. 2011;79:29–35.PubMedCrossRef
6.
Rodríguez Martínez de Llano S, Jiménez-Vicioso A, Mahmood S, Carreras-Delgado JL. Clinical impact of 18F-FDG PET in management of patients with renal cell carcinoma. Rev Esp Med. Nucl 2010;29:12–9.
7.
Fuccio C, Ceci F, Castellucci P, Spinapolice EG, Palumbo R, D’Ambrosio D, et al. Restaging clear cell renal carcinoma with 18F-FDG PET/CT. Clin Nucl Med. 2014;39:e320–4.PubMedCrossRef
8.
Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:464–73.PubMedCrossRef
9.
Noda Y, Kanematsu M, Goshima S, Suzui N, Hirose Y, Matsunaga K, et al. 18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas. Eur Radiol. 2015;25:3009–16.PubMedCrossRef
10.
Takahashi M, Kume H, Koyama K, Nakagawa T, Fujimura T, Morikawa T, et al. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT. Clin Nucl Med. 2015;40:936–40.PubMedPubMedCentralCrossRef
11.
Nakajima R, Abe K, Kondo T, Tanabe K, Sakai S. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma. Eur Radiol 2015 [Epub ahead of print].
12.
Mizuno T, Kamai T, Abe H, Sakamoto S, Kitajima K, Nishihara D, et al. Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer. BMC Cancer. 2015;15:1097.PubMedCrossRef
13.
Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, et al. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010;10:667.PubMedPubMedCentralCrossRef
14.
Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, et al. Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer. Clin Cancer Res. 2011;17:6021–8.PubMedCrossRef
15.
Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol). 2011;23:339–43.CrossRef
16.
Ueno D, Yao M, Tateishi U, Minamimoto R, Makiyama K, Hayashi N, et al. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer. 2012;12:162.PubMedPubMedCentralCrossRef
17.
Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Rathmell WK, McDermott DF, et al. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013;2:545–52.PubMedPubMedCentralCrossRef
18.
Yoon HJ, Paeng JC, Kwak C, Park YH, Kim TM, Lee SH, et al. Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy. Ann Nucl Med. 2013;27:748–55.PubMedCrossRef
19.
Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, et al. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009;24:137–44.PubMedCrossRef
20.
Farnebo J, Grybäck P, Harmenberg U, Laurell A, Wersäll P, Blomqvist LK, et al. Volumetric FDG-PET predicts overall and progression-free survival after 14 days of targeted therapy in metastatic renal cell carcinoma. BMC Cancer. 2014;14:408.PubMedPubMedCentralCrossRef
21.
Signoretti S, Regan M, Atkins M. Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. BJU Int. 2008;101:31–5.PubMedCrossRef
22.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:1220S–50S.CrossRef
23.
Hugonnet F, Fournier L, Medioni J, Smadja C, Hindié E, Huchet V, et al. Hypoxia in Renal Cancer Multicenter Group: metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med. 2011;201:1048–55.CrossRef
24.
Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, et al. FDG and FLT-PET for early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging. 2015;15:15.PubMedPubMedCentralCrossRef
25.
Middendorp M, Maute L, Sauter B, Vogl TJ, Grünwald F. Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med. 2010;24:441–6.PubMedCrossRef
26.
Oyama N, Takahara N, Hasegawa Y, Tanase K, Miwa Y, Akino H, et al. Assessment of therapeutic effect of sunitinib by 11C-Acetate PET compared with FDG PET imaging in a patient with metastatic renal cell carcinoma. Nucl Med Mol Imaging. 2011;45:217–9.PubMedPubMedCentralCrossRef
27.
Schuster DM, Nye JA, Nieh PT, Votaw JR, Halkar RK, Issa MM, et al. Initial experience with the radiotracer anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC) with PET in renal carcinoma. Mol Imaging Biol. 2009;11:434–8.PubMedCrossRef
28.
29.
Wang N, Jiang P, Lu Y. Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for detecting bladder lesions? A meta-analysis of the literature. Urol Int. 2014;92:143–9.PubMedCrossRef
30.
Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 2010;106:658–63.PubMedCrossRef
31.
Nayak B, Dogra PN, Naswa N, Kumar R. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique. Eur J Nucl Med Mol Imaging. 2013;40:386–93.PubMedCrossRef
32.
Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2012;81:2411–6.PubMedCrossRef
33.
Apolo AB, Riches J, Schöder H, Akin O, Trout A, Milowsky MI, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010;28:3973–8.PubMedPubMedCentralCrossRef
34.
Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S. Impact of 18F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. BJU Int. 2013;112:729–34.PubMedCrossRef
35.
Kollberg P, Almquist H, Bläckberg M, Cronberg C, Garpered S, Gudjonsson S, et al. [18F]Fluorodeoxyglucose - positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy. Scand J Urol. 2015;49:296–301.PubMedCrossRef
36.
Öztürk H, Karapolat I. Efficacy of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy. Exp Ther Med. 2015;9:717–24.PubMedPubMedCentral
37.
Mertens LS, Fioole-Bruining A, van Rhijn BW, Kerst JM, Bergman AM, Vogel WV, et al. FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer. J Urol. 2013;189:1687–91.PubMedCrossRef
38.
Giannatempo P, Alessi A, Miceli R, Raggi D, Farè E, Nicolai N, et al. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. Clin Genitourin Cancer. 2014;12:433–9.PubMedCrossRef
39.
Mertens LS, Mir MC, Scott AM, Lee ST, Fioole-Bruining A, Vegt E, et al. 18F-fluorodeoxyglucose–positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology. 2014;83:393–8.PubMedCrossRef
40.
Vargas HA, Akin O, Schöder H, Olgac S, Dalbagni G, Hricak H, et al. Prospective evaluation of MRI, 11C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol. 2012;81:4131–7.PubMedCrossRef
41.
Schöder H, Ong SC, Reuter VE, Cai S, Burnazi E, Dalbagni G, et al. Initial results with 11C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imaging Biol. 2012;14:245–51.PubMedCrossRef
42.
Graziani T, Ceci F, Lopes FL, Chichero J, Castellucci P, Schiavina R, et al. 11C-choline PET/CT for restaging of bladder cancer. Clin Nucl Med. 2015;40:e1–5.PubMedCrossRef
43.
Maurer T, Souvatzoglou M, Kübler H, Opercan K, Schmidt S, Herrmann K, et al. Diagnostic efficacy of 11C-choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol. 2012;61:1031–8.PubMedCrossRef
44.
Brunocilla E, Ceci F, Schiavina R, Castellucci P, Maffione AM, Cevenini M, et al. Diagnostic accuracy of 11C-choline PET/CT in preoperative lymph node staging of bladder cancer: a systematic comparison with contrast-enhanced CT and histologic findings. Clin Nucl Med. 2014;39:e308–12.PubMedCrossRef
45.
Maurer T, Horn T, Souvatzoglou M, Eiber M, Beer AJ, Heck MM, et al. Prognostic value of 11C-choline PET/CT and CT for predicting survival of bladder cancer patients treated with radical cystectomy. Urol Int. 2014;93:207–13.PubMedCrossRef
46.
Patil VV, Wang ZJ, Sollitto RA, Chuang KW, Konety BR, Hawkins RA, et al. 18F-FDG PET/CT of transitional cell carcinoma. AJR Am J Roentgenol. 2009;193:W497–504.PubMedCrossRef
47.
Asai S, Fukumoto T, Tanji N, Miura N, Miyagawa M, Nishimura K, et al. Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma. Int J Clin Oncol. 2015;20:1042–7.PubMedCrossRef
48.
Tanaka H, Yoshida S, Komai Y, Sakai Y, Urakami S, Yuasa T, et al. Clinical value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in upper tract urothelial carcinoma: impact on detection of metastases and patient management. Urol Int. 2016;96:65–72.PubMedCrossRef
49.
Kitajima K, Yamamoto S, Fukushima K, Yamakado K, Katsuura T, Igarashi Y, et al. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: comparison with contrast-enhanced CT. Eur J Radiol. 2016;85:593–8.PubMedCrossRef
50.
Jadvar H, Xiankui L, Shahinian A, Park R, Tohme M, Pinski J, et al. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging. 2005;4:91–7.PubMed
51.
Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40:S5–10.PubMedCrossRef
52.
Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, et al. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013;54:1195–201.PubMedPubMedCentralCrossRef
53.
Bertagna F, Piccardo A, Dib B, Bertoli M, Fracassi F, Bosio G, et al. Multicentre study of 18F-FDG-PET/CT prostate incidental uptake. Jpn J Radiol. 2015;33:538–46.PubMedCrossRef
54.
Bertagna F, Sadeghi R, Giovanella L, Treglia G. Incidental uptake of 18F-fluorodeoxyglucose in the prostate gland. Systematic review and meta-analysis on prevalence and risk of malignancy. Nuklearmedizin. 2014;53:249–58.PubMedCrossRef
55.
Hwang I, Chong A, Jung SI, Hwang EC, Kim SO, Kang TW, et al. Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images? Ann Nucl Med. 2013;27:140–5.PubMedCrossRef
56.
Kwon T, Jeong IG, You D, Hong JH, Ahn H, Kim CS. Prevalence and clinical significance of incidental 18F-fluoro-2-deoxyglucose uptake in prostate. Korean J Urol. 2015;56:288–94.PubMedPubMedCentralCrossRef
57.
Brown AM, Lindenberg ML, Sankineni S, Shih JH, Johnson LM, Pruthy S, et al. Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance? Abdom Imaging. 2015;40:3222–9.PubMedCrossRef
58.
Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59:913–8.PubMedCrossRef
59.
Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med. 2009;50:1585–93.PubMedPubMedCentralCrossRef
60.
Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med. 2006;47:1249–54.PubMed
61.
Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F Choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925–33.PubMedCrossRef
62.
Kitajima K, Murphy RC, Nathan MA. Choline PET/CT for imaging prostate cancer: an update. Ann Nucl Med. 2013;27:581–91.PubMedCrossRef
63.
Poulsen MH, Bouchelouche K, Hoilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, et al. [18F]-Fluorocholine positron-emission/computed tomography for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int. 2012;110:1666–71.PubMedCrossRef
64.
Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:13–26.PubMedCrossRef
65.
Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301–9.PubMedCrossRef
66.
Cimitan M, Evangelista L, Hodolič M, Mariani G, Baseric T, Bodanza V, et al. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients. J Nucl Med. 2015;56:209–15.PubMedCrossRef
67.
Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305–14.PubMedCrossRef
68.
Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [18F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol. 2012;81:700–8.PubMedCrossRef
69.
Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55:223–32.PubMedCrossRef
70.
Kitajima K, Murphy RC, Nathan MA, Sugimura K. Update on positron emission tomography for imaging of prostate cancer. Int J Urol. 2014;21:12–23.PubMedCrossRef
71.
Wachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging with recurrent prostate cancer. J Clin Oncol. 2006;24:2513–9.PubMedCrossRef
72.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed
73.
Tateishi U, Morita S, Taguri M, Shizukuishi K, Minamimoto R, Kawaguchi M, et al. A meta-analysis of 18F-fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010;24:523–31.PubMedCrossRef
74.
Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37:637–43.PubMedPubMedCentralCrossRef
75.
Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009;50:501–5.PubMedCrossRef
76.
Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, et al. Prospective comparison of 99mTc MDP scintigraphy, combined 18F-NaF and 18F-FDG PET/CT and whole-body MRI in patients with breast and prostate cancers. J Nucl Med. 2015;56:1862–8.PubMedCrossRef
77.
Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, et al. Tumor localization of 16beta-18Ffluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366–73.PubMed
78.
Oka S, Okudaira H, Yoshida Y, Schuster DM, Goodman MM, Shirakami Y. Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol. 2012;39:109–19.PubMedCrossRef
79.
Shoup TM, Olson J, Hoffman JM, Votaw J, Eshima D, Eshima L, et al. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331–8.PubMed
80.
Nanni C, Schiavina R, Boschi S, Ambrosini V, Pettinato C, Brunocilla E, et al. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging. 2013;40:S11–7.PubMedCrossRef
81.
Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer. 2014;12:106–10.PubMedCrossRef
82.
Bouchelouche K, Turkbey B, Choyke P, Capala J. Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep. 2010;11:180–90.PubMedPubMedCentralCrossRef
83.
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74.PubMedCrossRef
84.
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.PubMedCrossRef
85.
Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90.PubMedCrossRef
86.
Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, et al. Comparison of PSMA-based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-sensitive and castration-resistant metastatic prostate cancer. J Nucl Med. 2016;57:46–53.PubMedCrossRef
87.
Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, et al. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56:1003–10.PubMedPubMedCentralCrossRef
88.
Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, et al. [177Lu]Lutetium-labelled PSMA ligand induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987–8.PubMedCrossRef
89.
Boland GW, Dwamena BA, Jagtiani Sangwaiya M, Goehler AG, Blake MA, Hahn PF, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology. 2011;259:117–26.PubMedCrossRef
90.
Dong A, Cui Y, Wang Y, Zuo C, Bai Y. 18F-FDG PET/CT of adrenal lesions. AJR Am J Roentgenol. 2014;203:245–52.PubMedCrossRef
91.
Cistaro A, Niccoli Asabella A, Coppolino P, Quartuccio N, Altini C, Cucinotta M, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies—a multicenter experience. Hell J Nucl Med. 2015;18:97–102.PubMed
92.
Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL Jr, Macapinlac HA, Chuang HH. Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging. 2014;41:2066–73.PubMedCrossRef
93.
Ardito A, Massaglia C, Pelosi E, Zaggia B, Basile V, Brambilla R, et al. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. Eur J Endocrinol. 2015;173:749–56.PubMedCrossRef
94.
Park SY, Park BK, Kim CK. The value of adding 18F-FDG PET/CT to adrenal protocol CT for characterizing adrenal metastasis (≥ 10 mm) in oncologic patients. AJR Am J Roentgenol. 2014;202:W153–60.PubMedCrossRef
95.
Ambrosini V, Zucchini G, Nicolini S, Berselli A, Nanni C, Allegri V, et al. 18F-FDG PET/CT impact on testicular tumours clinical management. Eur J Nucl Med Mol Imaging. 2014;41:668–73.PubMedCrossRef
96.
Müller J, Schrader AJ, Jentzmik F, Schrader M. Assessment of residual tumours after systemic treatment of metastatic seminoma: 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography—meta-analysis of diagnostic value. Urologe A. 2011;50:322–7.PubMedCrossRef
97.
Treglia G, Sadeghi R, Annunziata S, Caldarella C, Bertagna F, Giovanella L. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis. Biomed Res Int. 2014;2014:852681.PubMedPubMedCentralCrossRef
98.
Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol. 2008;26:5930–5.PubMedCrossRef
99.
Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, et al. 2-18Fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol. 2012;23:59–64.PubMedCrossRef
100.
Antunes J, Viswanath S, Rusu M, Valls L, Hoimes C, Avril N, et al. Radiomics analysis on FLT-PET/MRI for characterization of early treatment response in renal cell carcinoma: a proof-of-concept study. Transl Oncol. 2016;9:155–62.PubMedPubMedCentralCrossRef
101.
Rosenkrantz AB, Balar AV, Huang WC, Jackson K, Friedman KP. Comparison of coregistration accuracy of pelvic structures between sequential and simultaneous imaging during hybrid PET/MRI in patients with bladder cancer. Clin Nucl Med. 2015;40:637–41.PubMedPubMedCentralCrossRef
102.
Souvatzoglou M, Eiber M, Martinez-Moeller A, Fürst S, Holzapfel K, Maurer T, et al. PET/MR in prostate cancer: technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging. 2013;40:79–88.CrossRef
103.
Wetter A, Lipponer C, Nensa F, Heusch P, Rübben H, Altenbernd JC, et al. Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:79–88.PubMedCrossRef
104.
Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:70–83.PubMedCrossRef
105.
Magnaldi S, Mayerhoefer ME, Khameneh A, Schuetz M, Javor D, Mitterhauser M, et al. 18F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas. Anticancer Res. 2014;34:791–5.PubMed
Metadata
Title
Update on advances in molecular PET in urological oncology
Authors
Kazuhiro Kitajima
Shingo Yamamoto
Kazuhito Fukushima
Ryogo Minamimoto
Takao Kamai
Hossein Jadvar
Publication date
01-07-2016
Publisher
Springer Japan
Published in
Japanese Journal of Radiology / Issue 7/2016
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-016-0553-3

Other articles of this Issue 7/2016

Japanese Journal of Radiology 7/2016 Go to the issue

Original Article

How can we reduce the pain associated with FNA biopsy? Comparison of parallel and perpendicular method

Technical Note

Image quality and variability for routine diagnostic FDG-PET scans in a Japanese community hospital: current status and possibility of improvement

Original Article

Homogeneously enhancing breast lesions on contrast enhanced US: differential diagnosis by conventional and contrast enhanced US findings

Review

Variants of meningiomas: a review of imaging findings and clinical features

Original Article

Perioperative and follow-up results in carotid artery stenting with contralateral carotid occlusion

Original Article

A new endovascular strategy utilizing a hybrid procedure for long segmental occlusion by acute arterial thromboembolism in the lower extremity